MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 127209 | Name: Traxanox

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Traxanox is a diuretic agent possessing an uricosuric effect in animals.

Chemical Structure

Traxanox
Traxanox
CAS#58712-69-9 (free base)

Theoretical Analysis

MedKoo Cat#: 127209

Name: Traxanox

CAS#: 58712-69-9 (free base)

Chemical Formula: C13H6ClN5O2

Exact Mass: 299.0210

Molecular Weight: 299.67

Elemental Analysis: C, 52.10; H, 2.02; Cl, 11.83; N, 23.37; O, 10.68

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
70502-82-8 (sodium) 58712-69-9 (free base)
Synonym
TRAXANOX; traxanox [INN]; TRAXANOX [MI]
IUPAC/Chemical Name
9-chloro-7-(1H-tetrazol-5-yl)-5H-chromeno[2,3-b]pyridin-5-one
InChi Key
MLCGWPUVZKTVLO-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H6ClN5O2/c14-9-5-6(12-16-18-19-17-12)4-8-10(20)7-2-1-3-15-13(7)21-11(8)9/h1-5H,(H,16,17,18,19)
SMILES Code
ClC1=CC(=CC2=C1OC3=NC=CC=C3C2=O)C4=NN=NN4
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 299.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Fujimura A, Ebihara A, Hino N, Koike Y. Effects of traxanox sodium on blood pressure and serum uric acid in hypertensive patients: a preliminary study. J Clin Pharmacol. 1989 Apr;29(4):327-30. PubMed PMID: 2723121. 2: Hisadome M, Terasawa M, Goto K, Kawazoe Y, Okumoto T. Stimulation of phagocytic activity of leukocytes and macrophages by traxanox sodium in mice and rats. Jpn J Pharmacol. 1989 Feb;49(2):275-84. PubMed PMID: 2733265. 3: Terasawa M, Tomomatsu N, Maruyama Y. [Effects of traxanox sodium on experimental nasal allergy]. Nihon Yakurigaku Zasshi. 1988 Jul;92(1):11-6. Japanese. PubMed PMID: 3220322. 4: Ebihara A, Tsuru M, Ohashi K, Fujimura A, Kondo K. Diuretic and uricosuric effects of traxanox sodium in healthy subjects. Single dose study. Arzneimittelforschung. 1987 Dec;37(12):1388-91. PubMed PMID: 3329516. 5: Church MK, Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol. 1987 Feb;90(2):421-9. PubMed PMID: 2435353; PubMed Central PMCID: PMC1916952. 6: Terasawa M, Imayoshi T, Maruyama Y, Abe C. [Effect of traxanox sodium on inflammatory response]. Nihon Yakurigaku Zasshi. 1985 Nov;86(5):329-40. Japanese. PubMed PMID: 2867959. 7: Terasawa M, Imayoshi T, Goto K. [Effect of traxanox sodium on SRS-A release in bronchial and peritoneal anaphylaxis]. Nihon Yakurigaku Zasshi. 1983 Jul;82(1):93-101. Japanese. PubMed PMID: 6194083. 8: Nakamura T, Miura Y, Aihara K, Satoh H, Goto K, Tsumagari T. [General pharmacological actions of traxanox sodium. II. Effects on the cardiovascular system]. Nihon Yakurigaku Zasshi. 1983 Jul;82(1):79-92. Japanese. PubMed PMID: 6137441. 9: Goto K, Osuga K, Haga K, Tsumagari T. [General pharmacology of traxanox sodium. I. Effects on the central, somatic, and autonomic nervous systems, digestive system, urologic organs, and reproductive system]. Nihon Yakurigaku Zasshi. 1983 May;81(5):343-63. Japanese. PubMed PMID: 6629211. 10: Ikegami K, Hirano S, Hasegawa G. The effects of traxanox sodium of cyclic AMP phosphodiesterase and the concentration of cyclic AMP in the plasma of rats. Chem Pharm Bull (Tokyo). 1983 Feb;31(2):752-5. PubMed PMID: 6309423. 11: Terasawa M, Goto K, Maruyama Y. [[Effect of traxanox sodium on type I-IV allergic reactions. Studies on anti-allergic agents VII]. Nihon Yakurigaku Zasshi. 1982 Dec;80(6):417-27. Japanese. PubMed PMID: 6219052. 12: Goto K, Hisadome M, Terasawa M. Inhibitory effect of traxanox sodium on IgE-mediated histamine release from passively-sensitized mast cells of the rat in vitro. Int Arch Allergy Appl Immunol. 1982;68(4):332-7. PubMed PMID: 6178699. 13: Goto K, Terasawa M, Komori A, Maruyama Y. [Effect of predosing with Y-12,141 on its antiallergic activity. --Studies on anti-allergic agents(IV)-- (author's transl)]. Nihon Yakurigaku Zasshi. 1981 Feb;77(2):123-9. Japanese. PubMed PMID: 6786963. 14: Goto K, Terasawa M, Kadobe Y, Maruyama Y. Anti-anaphylactic activities of a new benzopyranopyridine derivative Y-12,141 in rats and guinea pigs. Jpn J Pharmacol. 1980 Aug;30(4):537-47. PubMed PMID: 6162988.